Cell Phone Radiofrequency Radiation Exposure and Brain Glucose Metabolism

Abstract Background The Multidomain Alzheimer Preventive Trial (MAPT) was designed to assess the efficacy of omega-3 fatty acid supplementation, multidomain intervention (MI), or a combination of both on cognition. Although the MAPT study was negative, an effect of MI in maintaining cognitive functions compared to placebo group was showed in positive amyloid subjects. A FDG PET study (MAPT-NI) was implemented to test the impact of MI on brain glucose metabolism. Methods MAPT-NI was a randomized, controlled parallel-group single-center study, exploring the effect of MI on brain glucose metabolism. Participants were non-demented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. Participants were randomly assigned (1:1) to “MI group” or “No MI group.” The MI consisted of group sessions focusing on 3 domains: cognitive stimulation, physical activity, nutrition, and a preventive consultation. [18F]FDG PET scans were performed at baseline, 6 months, and 12 months, and cerebral magnetic resonance imaging scans at baseline. The primary objective was to evaluate the MI effect on brain glucose metabolism assessed by [18F]FDG PET imaging at 6 months. The primary outcome was the quantification of regional metabolism rate for glucose in cerebral regions involved early in Alzheimer disease by relative semi-quantitative SUVr (FDG-based AD biomarker). An exploratory voxel-wise analysis was performed to assess the effect of MI on brain glucose metabolism without anatomical hypothesis. Results The intention-to-treat population included 67 subjects (34 in the MI group and 33 in the No MI group. No significant MI effect was observed on primary outcome at 6 months. In the exploratory voxel-wise analysis, we observed a difference in favor of MI group on the change of cerebral glucose metabolism in limbic lobe (right hippocampus, right posterior cingulate, left posterior parahippocampal gyrus) at 6 months. Conclusions MI failed to show an effect on metabolism in FDG-based AD biomarker, but exploratory analysis suggested positive effect on limbic system metabolism. This finding could suggest a delay effect of MI on AD progression. Trial registration ClinicalTrials.gov Identifier, NCT01513252.

Download Full-text

Highly palatable diet changes brain glucose metabolism in mice

Alzheimer s & Dementia ◽

10.1002/alz.039786 ◽

2020 ◽

Vol 16 (S10) ◽

Author(s):

Sarah Wehle Gehres ◽

Andreia Silva da Rocha ◽

Yuri Elias Rodrigues ◽

Guilherme G Schu Peixoto ◽

Afonso Kopczynski Carvalho ◽

...

Keyword(s):

Glucose Metabolism ◽

Brain Glucose ◽

Brain Glucose Metabolism ◽

Palatable Diet ◽

Highly Palatable Diet

Download Full-text

Correlation between brain glucose metabolism (18F-FDG) and cerebral blood flow with amyloid tracers (18F-Florbetapir) in clinical routine: Preliminary evidences

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) ◽

10.1016/j.remnie.2021.03.016 ◽

2021 ◽

Author(s):

Domenico Albano ◽

Enrico Premi ◽

Alessia Peli ◽

Luca Camoni ◽

Francesco Bertagna ◽

...

Keyword(s):

Blood Flow ◽

Cerebral Blood Flow ◽

Glucose Metabolism ◽

Clinical Routine ◽

Brain Glucose ◽

Brain Glucose Metabolism ◽

18F Fdg

Download Full-text